cycloserine has been researched along with bedaquiline in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 3 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Castagnolo, D; Denny, WA; Dos Santos, JL; Fernandes, GFS; Thompson, AM | 1 |
| Andries, K; Bantubani, N; De Marez, T; Diacon, AH; Donald, PR; Grobusch, M; Lounis, N; Mahanyele, R; McNeeley, DF; Meyvisch, P; Narasimooloo, R; Patientia, RF; Pym, A; van Heeswijk, R | 1 |
| Khalid, UK; Kumar Verma, A; Mathuria, KK; Munjal, S; Myneedu, VP; Puri, MM; Sarin, R; Singla, N; Singla, R; Vohra, V | 1 |
| Martins Dos Santos, VAP; Rienksma, RA; Schaap, PJ; Suarez-Diez, M | 1 |
| Dhamija, RK; Garg, D; Saroha, D; Singh, AK | 1 |
| Basdeo, SA; Cahill, C; Cox, DJ; Gogan, KM; Gordon, SV; Keane, J; O'Connell, F; O'Sullivan, J; Phelan, JJ | 1 |
1 review(s) available for cycloserine and bedaquiline
| Article | Year |
|---|---|
Tuberculosis Drug Discovery: Challenges and New Horizons.
Topics: Antitubercular Agents; COVID-19 Drug Treatment; Drug Discovery; Humans; Mycobacterium tuberculosis; Tuberculosis | 2022 |
1 trial(s) available for cycloserine and bedaquiline
| Article | Year |
|---|---|
Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance.
Topics: Antitubercular Agents; Clarithromycin; Cycloserine; Dapsone; Diarylquinolines; Erythromycin; Female; Humans; Isoxazoles; Male; Ofloxacin; Oxazolidinones; Quinolines; Tuberculosis, Multidrug-Resistant | 2012 |
4 other study(ies) available for cycloserine and bedaquiline
| Article | Year |
|---|---|
Initial experience of bedaquiline implementation under the National TB Programme at NITRD, Delhi, India.
Topics: Adult; Antitubercular Agents; Cardiotoxicity; Clofazimine; Cycloserine; Diarylquinolines; Drug Therapy, Combination; Electrocardiography; Ethionamide; Female; Humans; India; Linezolid; Male; Moxifloxacin; National Health Programs; Sputum; Time Factors; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2019 |
Modeling Host-Pathogen Interaction to Elucidate the Metabolic Drug Response of Intracellular
Topics: Adenosine Triphosphatases; Amides; Amino Acids; Antitubercular Agents; Cycloserine; Diarylquinolines; Drug Tolerance; Ethambutol; Ethionamide; Gene Expression Profiling; Gene Expression Regulation, Bacterial; Host-Pathogen Interactions; Humans; Isoniazid; Isoxazoles; Metabolic Networks and Pathways; Models, Biological; Mycobacterium bovis; Mycobacterium tuberculosis; Oxazolidinones; Spiro Compounds; Thiazines; Tuberculosis | 2019 |
Irreversible neuropathy in extremely-drug resistant tuberculosis: An unfortunate clinical conundrum.
Topics: Adult; Aminosalicylic Acid; Antitubercular Agents; Clofazimine; Cycloserine; Deprescriptions; Diarylquinolines; Ethionamide; Extensively Drug-Resistant Tuberculosis; Female; Humans; Kanamycin; Linezolid; Neural Conduction; Neurotoxicity Syndromes; Peripheral Nervous System Diseases; Pyrazinamide; Pyridoxine; Tuberculosis, Pulmonary | 2020 |
The Iron Chelator Desferrioxamine Increases the Efficacy of Bedaquiline in Primary Human Macrophages Infected with BCG.
Topics: Amikacin; Antitubercular Agents; Bacterial Load; Cell Survival; Clofazimine; Cycloserine; Deferoxamine; Diarylquinolines; Drug Resistance, Bacterial; Drug Synergism; Gene Expression; Humans; Interferon-gamma; Interleukin-1beta; Interleukin-6; Iron; Iron Chelating Agents; Linezolid; Macrophages; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium bovis; Primary Cell Culture; Pyrazinamide | 2021 |